DE602005017131D1 - Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose - Google Patents

Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose

Info

Publication number
DE602005017131D1
DE602005017131D1 DE602005017131T DE602005017131T DE602005017131D1 DE 602005017131 D1 DE602005017131 D1 DE 602005017131D1 DE 602005017131 T DE602005017131 T DE 602005017131T DE 602005017131 T DE602005017131 T DE 602005017131T DE 602005017131 D1 DE602005017131 D1 DE 602005017131D1
Authority
DE
Germany
Prior art keywords
adefovir
tenofovir
breast cancer
viruses
connection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005017131T
Other languages
German (de)
English (en)
Inventor
Tomas Cihlar
Janet L Douglas
Craig S Gibbs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of DE602005017131D1 publication Critical patent/DE602005017131D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE602005017131T 2004-01-21 2005-01-21 Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose Expired - Lifetime DE602005017131D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53806604P 2004-01-21 2004-01-21
PCT/US2005/002043 WO2005072748A1 (en) 2004-01-21 2005-01-21 Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis

Publications (1)

Publication Number Publication Date
DE602005017131D1 true DE602005017131D1 (de) 2009-11-26

Family

ID=34825960

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005017131T Expired - Lifetime DE602005017131D1 (de) 2004-01-21 2005-01-21 Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose

Country Status (10)

Country Link
US (2) US20070281911A1 (https=)
EP (1) EP1732569B1 (https=)
JP (1) JP2007518815A (https=)
AT (1) ATE445404T1 (https=)
AU (1) AU2005209256B2 (https=)
CA (1) CA2553455A1 (https=)
DE (1) DE602005017131D1 (https=)
ES (1) ES2334149T3 (https=)
NZ (1) NZ548532A (https=)
WO (1) WO2005072748A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114065A2 (en) * 2005-04-25 2006-11-02 Institute Of Organic Chemistry And Biochemistry A Cademy Of Sciences Of The Czech Republic Use of compounds to inhibit neoplasia
RU2301088C2 (ru) * 2005-09-01 2007-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения рецидива рака молочной железы
SI2020996T1 (sl) 2006-05-16 2012-03-30 Gilead Sciences Inc Postopek in sestavki za zdravljenje hematološkihmalignosti
WO2011044125A1 (en) * 2009-10-05 2011-04-14 Ambergen, Inc. A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens
EP2625292B1 (en) 2010-10-07 2018-12-05 The General Hospital Corporation Biomarkers of cancer
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ N4-ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
KR102196711B1 (ko) * 2018-08-30 2020-12-30 가톨릭대학교 산학협력단 테노포비르 디소프록실 푸마르산을 유효성분으로 함유하는, 간섬유증 예방 또는 치료용 약학적 조성물
US20220143050A1 (en) * 2019-02-22 2022-05-12 Kazumoto Murata mTOR Inhibitor
WO2021003421A1 (en) * 2019-07-02 2021-01-07 Virago Vax Inc. Mammary tumor virus suppression
US12016844B2 (en) 2019-07-02 2024-06-25 Virago Vax Inc. Mammary tumor virus suppression
US12029783B2 (en) 2019-07-02 2024-07-09 Virago Vax Inc. Mammary tumor virus vaccine
IL315480A (en) 2022-03-15 2024-11-01 Rome Therapeutics Inc Compounds and methods for treating disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60038889D1 (de) * 1999-06-01 2008-06-26 Ochsner Med Found Alton Identifizierung eines neuartigen retrovirus welcher mit primärer leberzirrhose sowie autoimmunerkrankungen einhergeht
EP1190055B1 (en) * 1999-06-30 2008-06-25 The Administrators Of The Tulane Educational Fund Human endogenous retrovirus
US20020119443A1 (en) * 2000-07-21 2002-08-29 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
EP2223927B1 (en) * 2002-05-13 2014-10-15 Metabasis Therapeutics, Inc. Salts of a phosphonic acid based prodrug of PMEA

Also Published As

Publication number Publication date
NZ548532A (en) 2009-09-25
EP1732569B1 (en) 2009-10-14
ATE445404T1 (de) 2009-10-15
AU2005209256B2 (en) 2010-11-18
US20070281911A1 (en) 2007-12-06
ES2334149T3 (es) 2010-03-05
AU2005209256A1 (en) 2005-08-11
HK1099228A1 (en) 2007-08-10
US20050239753A1 (en) 2005-10-27
WO2005072748A1 (en) 2005-08-11
EP1732569A1 (en) 2006-12-20
JP2007518815A (ja) 2007-07-12
CA2553455A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
DE602005017131D1 (de) Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
BR112023000205A2 (pt) Misturas fungicidas
IS7997A (is) Granisetron lyfjaplástur
MX2018009496A (es) Degradadores selectivos del receptor de estrogeno y sus usos.
CY1112743T1 (el) Στερεοϊσομερως εμπλουτισμενες ενωσεις 3-αμινοκαρβονυλ δικυκλοεπτενο πυριμιδινοδιαμινης και οι χρησεις τους
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
BRPI0515319A (pt) análogos de quinolona
CY1108399T1 (el) Τετραϋδροπυριδοθειοφαινια
CY1109440T1 (el) Φωσφοϊνδολες ως αναστολεις hiv
ATE541848T1 (de) Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
UY29417A1 (es) Agentes endoparasiticidas
WO2019108004A3 (en) Therapeutic agent for blood cancer
DK1893213T3 (da) Kombination af pyrimidylaminobenzamidforbindelser og imatinib til behandling eller forebyggelse af proliferative sygdomme
MY166063A (en) Intravenous antiviral treatments
MX2007004461A (es) Composiciones farmaceuticas a base de antagonistas de nk2 para uso pediatrico.
ECSP077378A (es) Isoxazoles sustituidos como fungicidas
RU2010139486A (ru) Способ коррекции гиперэстрадиолемии и нормогонадотропного гипогонадизма у мужчин
UY28563A1 (es) Complejos metálicos de paladio y platino con tiosemicarbazonas derivadas de 5-nitrofurano, procedimiento de preparación y utilización
UA89625C2 (ru) Фосфонаты, монофосфонамидаты, бисфосфонамидаты для лечения вирусных заболеваний
TR200805408U (tr) Kendi̇nden kapsüllü taşima kulbu
TR200700817U (tr) Tedrici kemik düzeltme düzeneği

Legal Events

Date Code Title Description
8364 No opposition during term of opposition